Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.29B 11.36B 10.45B 19.74B 1,352B 20.05B 136B 53.18B 661B 52.65B 51.5B 2,279B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.43B 10.56B 9.71B 18.36B 1,257B 18.64B 126B 49.44B 615B 48.95B 47.89B 2,119B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Issuer sale

Executive Vice President & CFO

75,024 0.0706%
2/4/25 Issuer sale

Director

242,551 0.2281%
2/4/25 Issuer sale

Chief Executive Officer

2,048,863 1.9269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+109.18% 14.02B
-0.67%+1.15%+23.89%-6.52% 68.85B
-0.54%+0.38%+36.12%+192.81% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-0.58%-0.23%-52.36%-53.82% 41.24B
-2.93%+0.40%+59.97%-27.79% 30.41B
-3.77%-12.86%+90.31%-52.47% 24.53B
-1.36%-0.91%+70.42%+83.86% 23.42B
+3.99%+3.12%+3.87%+200.81% 19.75B
+0.26%-1.74%+70.47%+125.19% 16.57B
Average -0.56%-0.92%+33.72%+60.58% 33.44B
Weighted average by Cap. -0.89%-0.44%+29.31%+48.70%

Financials

2023 2024
Net sales 464M 407M 376M 346M 654M 44.78B 664M 4.49B 1.76B 21.89B 1.74B 1.71B 75.46B 681M 597M 552M 507M 959M 65.66B 974M 6.59B 2.58B 32.1B 2.56B 2.5B 111B
Net income -140M -122M -113M -104M -197M -13.47B -200M -1.35B -530M -6.58B -524M -513M -22.7B -74.68M -65.44M -60.51M -55.63M -105M -7.2B -107M -722M -283M -3.52B -280M -274M -12.14B
Net Debt -481M -422M -390M -358M -677M -46.39B -688M -4.65B -1.82B -22.68B -1.81B -1.77B -78.16B -984M -862M -797M -733M -1.39B -94.9B -1.41B -9.52B -3.73B -46.39B -3.7B -3.61B -160B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock